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Abstract
Background: Lung fibrosis is characterized by tissue remodeling resulting from an imbalance
between synthesis and degradation of extracellular organic matrices. To examine whether
cathepsin(s) (Cat) are important in the development of pulmonary fibrosis, we assessed the
expression of four Cat known for their collagenolytic activity in a model of silica-induced lung
fibrosis.
Methods: Different strains of mice were transorally instilled with 2.5 mg crystalline silica or other
particles. Cat expression (Cat K, S, L and B) was quantified in lung tissue and isolated pulmonary
cells by quantitative RT-PCR. In vitro, we assessed the effect of different cytokines, involved in lung
inflammatory and fibrotic responses, on the expression of Cat K by alveolar macrophages and
fibroblasts.
Results: In lung tissue, Cat K transcript was the most strongly upregulated in response to silica,
and this upregulation was intimately related to the fibrotic process. In mouse strains known for
their differential response to silica, we showed that the level of Cat K expression following silica
treatment was inversely related to the level of TGF-β expression and the susceptibility of these
strains to develop fibrosis. Pulmonary macrophages and fibroblasts were identified as Cat K
overproducing cells in the lung of silicotic mice. In vitro, Cat K was downregulated in mouse and
human lung fibroblasts by the profibrotic growth factor TGF-β1.
Conclusion: Altogether, these data suggest that while Cat K may contribute to control lung
fibrosis, TGF-β appears to limit its overexpression in response to silica particles.
Background
Tissue remodeling is a dynamic process common to sev-
eral pulmonary disorders, such as asthma and lung fibro-
sis. It generally follows an inflammatory injury and
involves an unbalanced repair process characterized by an
inappropriate production/degradation of the organic
matrix, which leads to abnormal lung architecture and
impairment of lung function [1]. Remodeling involves
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destruction of basement membranes as well as of elastic
fibers, and the exaggerated accumulation of organic extra-
cellular matrices (ECM) [1-5]. During the fibrogenic proc-
ess, the pre-existing equilibrium between matrix synthesis
and degradation in the healthy lung [6] is disrupted, lead-
ing to an excessive accumulation of ECM. The secretion of
growth factors, such as transforming growth factor-β
(TGF-β) and platelet-derived growth factor (PDGF),
together with the modified expression of matrix degrad-
ing-related enzymes contribute to the increased produc-
tion by fibroblasts and pulmonary accumulation of ECM,
such as collagen [1].
Matrix metalloproteases (MMPs) have been extensively
studied for their role in ECM turnover in the lung and
other organs [7,8]. Several MMPs were found to be abnor-
mally regulated in human fibrotic diseases [9,10] and
rodent models of fibrosis [11-13]. Although the expres-
sion of most MMPs was observed to be increased in
fibrotic lungs, the expression of collagenases (MMP-1, 8,
13) appears to depend on the model or type of pathogen-
esis studied and the stage of the disease. The simultane-
ously increased expression of tissue inhibitors of
metalloproteases (TIMPs) led several authors to suggest
that an imbalance between MMPs and TIMPs occurring
during fibrogenesis could lead to abnormal lung remode-
ling [11,12,14,15]. Despite clues pointing to MMPs/
TIMPs as important players in the control of fibrosis, none
of them has been shown so far to exert a protective func-
tion in this process in vivo [16,17].
Since they have also been involved in the turnover/degra-
dation of ECM [18], lysosomal cysteine proteases could
also apply to play a role in the development of lung fibro-
sis. One of them, cathepsin K (Cat K), is the most potent
mammalian collagenase compared to other cysteine pro-
teases (Cat B, L and S) and MMPs [19,20]. Cat K plays a
pivotal role in bone remodeling. Indeed, mutations in the
Cat K gene were found to be responsible of pycnodysosto-
sis in humans [21] and of a similar bone phenotype in
mouse [22]. In a murine model of lung fibrosis induced
by bleomycin, this cathepsin was found to be induced in
the lung [23]. Recently, it was suggested to exert a protec-
tive role against matrix deposition during pulmonary
fibrosis, since lungs of Cat K deficient mice accumulated
more collagen than wild type animals in response to ble-
omycin [24].
The purpose of this work was to identify lysosomal
cysteine proteases potentially important in the develop-
ment of pulmonary fibrosis in a murine model induced
by the instillation of crystalline silica particles. Our study
revealed that Cat K transcripts are highly increased in the
lungs after silica treatment compared to Cat S, L and B and
that this upregulation is specific to the fibrotic process. We
also compared Cat K expression in "fibrosis-prone" and
"fibrosis-resistant" mouse strains, and identified cells
responsible for Cat K upregulation in the silicotic lung.
Finally, the regulation of Cat K expression by growth fac-
tors involved in the inflammatory and/or fibrotic reac-
tions was studied in vitro in both mouse and human
fibroblasts.
Methods
Animals and instillation method
C57BL/6 and BALB/c female mice were obtained from the
local breeding facility of the Ludwig Institute (Brussels,
Belgium). NMRI female mice were purchased from
Charles River Laboratories (Brussels, Belgium). Animals
were housed in positive pressure air-conditioned units
(25°C, 50% relative humidity) on a 12 h light/dark cycle.
Eight to ten week-old mice were used. Crystalline silica
(DQ12, d50 = 2.2 µm, a gift from Dr. Armbruster, Essen,
Germany), manganese dioxide (MnO2) or tungsten car-
bide (WC) particles were heated at 200°C for 2 h before
use to remove any trace of endotoxin. For instillation, ani-
mals were anesthetized with a mix of Ketalar (n.v. Warner-
Lambert, Zaventem, Belgium) and Rompun (Bayer,
Leverkusen, Germany) (respectively 1 and 0.2 mg/mouse
i.p.). Particles were suspended in sterile phosphate buff-
ered saline (PBS) and 2.5 mg particles/mouse (60 µl/
mouse) were instilled into the lungs via the trachea by
transoral instillation. Control mice were instilled with a
corresponding volume of PBS. At selected time intervals,
mice were sacrificed with an overdose of sodium pento-
barbital (11 mg/animal given i.p.).
Lung homogenates
Whole lungs were perfused with 5 ml sterile 0.9 % NaCl
and then excised. The left lobe was placed in Trizol (Invit-
rogen, Paisley, USA) for subsequent RNA extraction and
the right lobes transferred to 3 ml cold PBS. For the Cat K
activity test, entire lungs were collected in PBS. Lungs in
PBS were homogenized on ice with an Ultra-Turrax T25
homogenizer (Janke & Kunkel, Brussels, Belgium) and
stored at -80°C.
Bronchoalveolar lavage (BAL) cells and macrophage 
enrichment
Bronchoalveolar lavages were performed by cannulating
the trachea and infusing the lungs with four volumes of 1
ml sterile 0.9 % NaCl. Lavages collected from control or
treated mice were pooled and centrifuged 10 min at 400 g
(4°C). Cell pellets were rinsed with sterile PBS. To deter-
mine the proportion of macrophages, cells were pelleted
onto glass slides by cytocentrifugation and counted by
light microscopy after Diff-Quick staining (200 cells
counted, Dade Behring AG, Düdingen, Switzerland). For
RNA extraction of total BAL cells, RLT lysis buffer (RNeasy
mini kit, Qiagen, Maryland, USA) was directly added toRespiratory Research 2005, 6:84 http://respiratory-research.com/content/6/1/84
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the cell pellets. For macrophage enrichment, cell pellets
were resuspended in an adequate volume of Dulbecco's
modified Eagle's medium (DMEM, Invitrogen) supple-
mented with 10 % fetal bovine serum (FBS, Invitrogen), 2
mM L-glutamine (Invitrogen), 50 U/ml penicillin and 50
µg/ml streptomycin (Invitrogen) to obtain a suspension
of 106 macrophages/ml. Four ml of this alveolar cell sus-
pension were seeded into 6-well culture plates and incu-
bated at 37°C under 5% CO2. After 2 h, the cultures were
washed twice with PBS to remove non-adherent cells, and
adherent cells were lysed with RLT buffer.
Fibroblast culture
Perfused whole lungs were minced with scissors and sus-
pended in DMEM containing 10 % FBS, 50 U/ml penicil-
lin and 50 µg/ml streptomycin (10 ml medium/lung).
Twenty ml of this suspension was transferred to a flat tis-
sue culture flask and incubated at 37°C under 5% CO2.
The medium was replaced every week. After 2 to 3 weeks,
cells were washed twice with 10 ml PBS, detached with
0.05 % trypsin (10 ml, Invitrogen) and then collected
with 10 ml DMEM supplemented with 10 % FBS. The cell
suspension was passed trough a sterile 70 µm nylon filter
and centrifuged 10 min at 260 g (4°C). After resuspension
of cell pellets in DMEM, cell number and viability were
determined with trypan blue (Sigma, St Louis, USA). Sus-
pensions were adjusted to 5.105  fibroblasts/3 ml of
DMEM containing 10 % FBS, 50 U/ml penicillin and 50
µg/ml streptomycin. Aliquots of 3 ml were seeded into 6-
well culture plates and incubated at 37°C under 5% CO2.
When no treatment was applied to the fibroblasts, the
cells were washed after 24 h and lysed with RLT buffer. To
test the effect of cytokines on Cat K expression, cells were
grown to pre-confluence, rinsed twice with PBS and then
supplemented with fresh medium (DMEM containing 2
mM L- glutamine, 200 µM proline (Sigma), 50 µg/ml L-
ascorbic acid (Sigma), 50 U/ml penicillin and 50 µg/ml
streptomycin) alone (non-treated) or containing recom-
binant human interleukin-1β (IL-1β, Roche, Vilvoorde,
Belgium), mouse tumor necrosis factor-α (TNF-α, R&D
Systems), recombinant mouse IL-4 (R&D Systems, Min-
neapolis, USA), recombinant mouse IL-9 [25], prostaglan-
din E2 (PGE2, Sigma) or human TGF-β1 (R&D Systems).
After 24 h incubation, fibroblasts were washed with PBS
and lysed with RLT buffer. Human fibroblasts from
healthy lung tissue were obtained as described in Bühling
et al. [24] and incubated with TGF-β1. After 48 h, fibrob-
lasts were washed with PBS and lysed with RLT buffer for
subsequent RNA extraction.
Hydroxyproline assay
Collagen deposition was estimated by measuring hydrox-
yproline content in lungs homogenized in PBS. Hydroxy-
proline was assessed by high-pressure liquid
chromatography analysis on hydrolyzed lung homoge-
nates (6 N HCl at 108°C during 24 h) as previously
described [26].
Total TGF-β1 lung content
Total TGF-β1 lung contents were measured in lung
homogenates by ELISA (Enzyme-linked immunosorbent
assay) using the Quantikine human TGF-β1 immu-
noassay (R&D systems, Wiesbaden-Nordenstadt, Ger-
many) according to manufacturer's instructions.
Total RNA extraction and quantification of cathepsin 
transcripts
Perfused left lung lobes were homogenized on ice in 3 ml
Trizol using an Ultra-Turrax T25. Total RNA extraction
was performed according to Trizol manufacturer's instruc-
tions. RNA from centrifuged BAL cells and cell cultures
was extracted with the RNeasy mini kit (Qiagen). Residual
DNA contamination was removed by treatment with
DNA-free (Ambion, Austin, USA). Between 100 ng and 1
µg of RNA was reverse transcribed with Superscript RNase
H- Reverse Transcriptase (Invitrogen) with 350 pmol ran-
dom hexamers (Eurogentec, Seraing, Belgium) in a final
volume of 25 µl. Resulting cDNA was then diluted 50×
and used as template in subsequent polymerase chain
reaction (PCR). Sequences of interest were amplified
using the following forward primers: AGA GGG AAA TCG
TGC GTG AC (mouse β-actin), ACT TGG GAG ACA TGA
CCA GTG A (mouse Cat K), CAC TGA GGT GAA ATA CCA
GGG TTC (mouse Cat S), CTC TGG AGC ATG GAG CTT
CTG (mouse Cat B), CTG TGA AGA ACC AGG GCC AG
(mouse Cat L), and reverse primers: CAA TAG TGA TGA
CCT GGC CGT (mouse β-actin), TCT TGA CTG GAG TAA
CGT ATC CTT TC (mouse Cat K), GAT GTA CTG GAA
AGC TTC GGT CA (mouse Cat S), CGC TGT AGG AAG
TGT ACC CAA AG (mouse Cat B), CCT TGA GCG TGA
GAA CAG TCC (mouse Cat L). PCR was primarily per-
formed with Platinum Taq DNA polymerase (Invitrogen)
according to manufacturer's instructions with the follow-
ing temperature program: 2 min 94°C, (30 s 94°C, 30 s
55°C, 20 s 72°C) ×40, 5 min 72°C. Amplified DNA frag-
ments were purified from a 1.5 % agarose gel with Nucle-
ospin Extract (Macherey-Nagel, Düren, Germany) and
then serially diluted to serve as standards in real-time
PCR. Reverse transcribed mRNAs were finally quantified
by real-time PCR using SYBR Green technology on an ABI
Prism 7000 Sequence Detection System (Applied Biosys-
tems, Foster City, USA) according to the following pro-
gram: 2 min 50°C, 10 min 95°C, (15 s 95°C, 1 min
60°C) ×40. Five µl of diluted cDNA or standards were
amplified with 300 nM of the described primers using
SYBR Green PCR Master Mix (Applied Biosystems) in a
total volume of 25 µl. PCR product specificity was verified
by taking a dissociation curve and by agarose gel electro-
phoresis. RT-PCR on RNA isolated from human fibrob-
lasts was performed as previously described [24]. ResultsRespiratory Research 2005, 6:84 http://respiratory-research.com/content/6/1/84
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were calculated as a ratio of cathepsin expression to the
expression of the reference gene, β-actin.
Cat K enzymatic activity
Whole lung homogenates were sonicated on ice for 3 s
and then centrifuged 5 min at 2600 g (4°C). Assays were
performed on resulting supernatants as previously
described [27,28]. Briefly, 200 µl samples were incubated
15 min with Cat K substrate, Z-GPR-AMC (80 µM, Bio-
mol, Plymouth Meeting, USA) in presence of the cysteine
proteases inhibitor, E64 (16 µM, Biomol) or the Cat B spe-
cific inhibitor, CA-074 (16 µM, Biomol) in a total volume
of 1 ml. The reaction was terminated by the addition of 2
ml stop buffer and the resulting fluorescence was meas-
ured using a SPF-500 ratio spectrofluorometer (Aminco,
Silver Spring, USA, excitation 365 nm, emission 440 nm).
Cat K enzymatic activities are presented as the difference
of fluorescence intensities between measurements in pres-
ence of CA-074 and in presence of E-64.
Statistics
Differences were evaluated using t tests and one-way anal-
ysis variance, followed by Dunnett's test, as appropriate.
Statistical significance was considered at P < 0.05. Data
analysis was performed with GraphPad InStat version
3.05 for Windows 95/NT (GraphPad Software, San Diego,
USA).
Results
Cat K is more strongly upregulated than Cat S, L and B 
during silica-induced fibrosis
To identify lysosomal cysteine proteases potentially
important in lung fibrosis, we first assessed the level of
cathepsin expression during the development of silica-
induced lung inflammation and fibrosis. C57BL/6 mice
were instilled with 2.5 mg silica particles or PBS (control)
and their lungs were collected after several time periods.
We chose to concentrate on three time points representa-
tive of different stages of the silicotic disease in mice [29].
The early inflammatory reaction was monitored 3 days
after instillation, the interface between the inflammatory
and the fibrotic process after 1 month, and the established
fibrosis at 2 months, as demonstrated later by the accu-
mulation of collagen in the lung. The establishment of
fibrosis in silica-treated mice was assessed by measuring
lung OH-proline content, which reflects collagen deposi-
tion. We and others have shown the good correlation
between this marker and histological fibrosis [30,31].
Two months after administration of silica particles, colla-
gen significantly accumulated in silicotic lungs to levels
twice that of healthy lungs (figure 1A). Cat K, L, S and B
transcripts were quantified in the lungs by RT-real-time
PCR at different time intervals after treatment. As shown
in figure 1B, Cat K was the most highly upregulated cathe-
psin at all evaluated time points after silica instillation.
Although Cat B and S were approximately overexpressed
2 fold after 1 and 2 months, Cat K reached levels up to 7
times higher than the controls. Cat K was found to be
upregulated in mice lungs as already as 3 days after silica
instillation. After its maximum was attained at the onset
of the fibrogenic process, i.e. at the interface between
inflammation and fibrosis (1 month), Cat K expression
was maintained at a high level at the fibrotic stage (2
months). No change was detected for Cat L.
To assess whether Cat K transcript upregulation was asso-
ciated with an increase of its enzymatic activity, we meas-
ured Cat K specific activity in whole lung homogenates.
We concentrated on 2 months after instillation since Cat
K expression is elevated at this time point and since 2
months represents the maximal collagen accumulation in
lungs among time points studied. Lungs obtained 2
months after silica treatment of C57BL/6 mice showed
significantly higher Cat K activity than lungs from control
mice (respectively 0.144 ± 0.0087 fluorescence units and
0.0325 ± 0.0075 fluorescence units, P < 0.001, n ≥ 4).
Cat K is specifically upregulated in response to fibrogenic 
particles
In a comparative mouse model described previously [29],
we tested whether the Cat K response was specific to the
development of lung fibrosis. Therefore, NMRI mice were
instilled with 2.5 mg of mineral particles inducing differ-
ent lung responses. Tungsten carbide (WC) treatment is
accompanied by no modification in inflammatory param-
eters and lung structure (noninflammatory model, NI).
While silica induces a chronic alveolitis accompanied by a
fibrogenic response (fibrosing alveolitis model, FA), man-
ganese dioxide (MnO2) induces an acute lung inflamma-
tory reaction without subsequent fibrosis (resolutive
alveolitis model, RA). Interestingly, Cat K transcript levels
were not significantly affected by the administration of
inert (NI) or inflammatory particles (RA) whereas admin-
istration of silica strongly upregulated the pulmonary
expression of Cat K 1 month after instillation (figure 2).
Cat B and Cat S expressions were only slightly increased to
similar levels both in the RA and FA models (data not
shown).
Cat K expression inversely correlates with the amplitude of 
the fibrotic response
We also examined Cat K expression in mice exhibiting low
and high response to silica-induced pulmonary fibrosis. It
is known that different strains of mice respond with vari-
able degrees of susceptibilities to experimental factors
inducing pulmonary fibrosis. Previous studies showed
that, in response to silica instillation, the C57BL/6 strain
displays a much more pronounced accumulation of colla-
gen in the lung than the BALB/c strain [32]. To test the
possible association between Cat K expression and theRespiratory Research 2005, 6:84 http://respiratory-research.com/content/6/1/84
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Cat K mRNA is strongly upregulated in the lungs of silica-treated mice Figure 1
Cat K mRNA is strongly upregulated in the lungs of silica-treated mice. C57BL/6 mice were instilled with PBS (control) or 2.5 
mg of crystalline silica. Lungs were collected at different time intervals after instillation. (A) OH-proline lung contents. ** P < 
0.01 for comparison between control and silica-treated mice. (B) Cat transcripts were quantified by RT-real-time PCR on RNA 
extracted from lung tissue. Results were calculated as a ratio of Cat expression to β-actin expression and expressed as per-
centage of controls. Values of 5 mice in each group are presented as means ± SEM. All levels of Cat expression were signifi-
cantly higher in silica-treated mice compared to control mice except for Cat L (all time points), and Cat B and S (at 3 days).
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amplitude of fibrosis in these mouse strains, BALB/c and
C57BL/6 mice were instilled with silica particles and ana-
lyzed as described above. OH-proline lung contents were
quantified 2 months after treatment in order to verify the
contrasting susceptibility of the both strains. Figure 3A
shows that the accumulation of collagen in C57BL/6
fibrotic lungs was significantly more important after silica
treatment than in BALB/c lungs. OH-proline levels in
BALB/c nearly remained at the control level. TGF-β is
thought to play a role in the differences of sensitivity in
response to fibrosing agents because it was found to be
more expressed in sensitive than in resistant mouse strains
treated with bleomycin or irradiation [33-35]. We meas-
ured TGF-β lung content in response to silica to verify this
hypothesis. One month after instillation, i.e. at the onset
of the establishment of fibrosis, total TGF-β1 level was
found to be significantly increased in C57BL/6 silicotic
lungs compared to control lungs and TGF-β1 lung content
in BALB/c mice remained unchanged (figure 3B). No sig-
nificant differences were observed between control and
treated mice 3 days and 2 months after instillation (data
not shown). Interestingly, Cat K transcripts were differen-
tially upregulated upon silica treatment in C57BL/6 and
BALB/c lungs. Although Cat K mRNA levels at 1 and 2
months were increased in both strains in response to sil-
ica, the overexpression was significantly higher in resistant
BALB/c mice than in sensitive C57BL/6 mice (figure 3C).
No such difference between the both strains was observed
after saline treatment (control situations) or 3 days after
silica treatment. We concluded that pulmonary collagen
contents and Cat K expression levels were inversely asso-
ciated in this murine model of lung fibrosis.
Pulmonary macrophages and fibroblasts overexpress Cat 
K in silicotic mice
Pulmonary macrophages and fibroblasts play important
roles in inflammatory and fibrogenic responses upon sil-
ica instillation by, respectively, producing fibrotic
mediators and components of the organic matrix, such as
collagen [36]. To determine which cells are responsible
for the increase of Cat K mRNA in the lung, we studied the
expression of this cathepsin in BAL leukocytes and fibrob-
lasts from control and silica-instilled C57BL/6 mice. Cat K
was found to be upregulated in BAL leukocytes collected
3 days and 1 month after instillation (Figure 4A). To fur-
ther identify Cat K producing cells, lung macrophages
were separated from other inflammatory cells by adher-
ence. Figure 4B revealed that at 1 month adherent silicotic
macrophages overexpress Cat K in comparison to adher-
ent control macrophages, indicating that pulmonary mac-
rophages are, at least in part, responsible for the Cat K
upregulation. The fact that Cat K expression was markedly
increased in the lung but not in BAL cells 2 months after
silica instillation (figure 1B vs. figure 4A), suggested that
other cells were involved in this process. In view of their
major role in the production of extracellular organic
matrices during fibrosis, Cat K expression was compared
in isolated control and silicotic lung fibroblasts. Cat K
mRNA levels were higher in fibroblasts from silica-treated
mice at a fibrotic stage (2 months) than in control fibrob-
lasts (figure 4C), demonstrating that lung fibroblasts are
also able to overexpress Cat K in response to silica
administration.
TGF-β1 downregulates Cat K in mouse and human lung 
fibroblasts
Pulmonary macrophages and fibroblasts were identified
as overproducing cells of Cat K transcripts. To identify
mediators that could be responsible for the regulation of
Cat K expression in the lung, cultured lung fibroblasts
from healthy C57BL/6 mice were treated with several
growth factors. While IL-1β, TNF-α and IL-4, known for
their implication in the extension of lung fibrosis [37,38],
had no or limited effect on Cat K expression, both concen-
trations of TGF-β1 (1 and 10 ng/ml) reduced Cat K expres-
sion (figure 5A). Moreover, TGF-β1 was also able to
downregulate Cat K in lung fibroblasts purified from mice
2 months after silica instillation, i.e. at the fibrotic stage of
the disease (figure 5B). No effect of this cytokine was
observed on Cat K expression in pulmonary macrophages
(data not shown). PGE2 and IL-9, two antifibrotic factors
[25,39], did not affect Cat K expression in mouse fibrob-
lasts (data not shown). We also measured the expression
of Cat K in cultures of human lung fibroblasts treated or
Pulmonary overexpression of Cat K is specific to a fibrotic  response of the lung Figure 2
Pulmonary overexpression of Cat K is specific to a fibrotic 
response of the lung. Quantification of Cat K transcripts in 
lung tissue from NMRI mice instilled with PBS (control), WC 
(non-inflammatory model, NI), MnO2 (resolutive alveolitis 
model, RA) or silica (fibrosing alveolitis model, FA) 1 month 
after instillation. Values of 4 mice in each group are pre-
sented as means ± SEM. * P < 0.05 compared to control 
values.
0
0,1
0,2
0,3
0,4
Control NI RA FA
C
a
t
 
K
/
E
-
a
c
t
i
n
 
e
x
p
r
e
s
s
i
o
n *Respiratory Research 2005, 6:84 http://respiratory-research.com/content/6/1/84
Page 7 of 13
(page number not for citation purposes)
Cat K is more strongly upregulated in response to silica in "fibrosis-resistant" than in "fibrosis-prone" mice Figure 3
Cat K is more strongly upregulated in response to silica in "fibrosis-resistant" than in "fibrosis-prone" mice. BALB/c and C57BL/
6 mice were instilled with PBS (control) or silica. (A) OH-proline lung contents 2 months after treatment. ** P < 0.01 for com-
parison of silica-treated mice between both strains. (B) Total TGF-β1 lung contents 1 month after instillation. ** P < 0.01 for 
comparison between silicotic and control lungs. (C) Cat K transcripts quantification on RNA extracted from lung tissue col-
lected at different time intervals after instillation. Ns not significant, * P < 0.05 for comparison of silica-treated mice between 
strains at 1 and 2 months. Cat K expressions are not (significantly) different between all control conditions whereas it is signif-
icantly upregulated in all silica-treated groups compared to corresponding control groups. Values of 4 to 5 control mice and 5 
to 6 silica-treated mice in each group are presented as means ± SEM.
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Cat K expression is higher in pulmonary macrophages and fibroblasts from silica-treated mice Figure 4
Cat K expression is higher in pulmonary macrophages and fibroblasts from silica-treated mice. Quantification of Cat K mRNA 
in pulmonary cells from C57BL/6 mice instilled with PBS (control) or silica. (A) Cat K expression in a pool of BAL leukocytes 
collected from 20 control mice and 10 silica-treated mice for each time point. (B) Cat K expression in adherent BAL cells 
(macrophages) collected 1 month after instillation of 40 control mice and 30 mice administered with silica. (C) Cat K expres-
sion in lung fibroblasts recovered 2 months after instillation from a pool of 9 control mice and 8 silica-treated mice. The results 
are representative of 3 independent experiments. (A), (B), (C) Values were measured 3 times for each condition and are pre-
sented as means ± SEM.
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not with TGF-β1. Like in mice, a similar trend was
observed in human lung fibroblasts obtained from a
healthy individual where this growth factor reduced Cat K
expression by 80% (P = 0.053, figure 6).
Discussion
Lung fibrosis is characterized by tissue remodeling result-
ing from the imbalance between synthesis and degrada-
tion of extracellular organic matrices. While several
mechanisms and mediators responsible for the stimula-
tion or inhibition of matrix production have been widely
studied, little information exists on the implication of
proteases in the limitation of matrix accumulation in the
fibrotic lung. In this study, we used a model of silica-
induced lung fibrosis to screen the expression of four lys-
osomal cysteine proteases known for their collagenolytic
activities in order to identify cathepsin(s) potentially
important in the development of pulmonary fibrosis.
Quantitative analysis of the cathepsin transcripts revealed
Cat K as the most strongly upregulated protease in
response to silica compared to Cat S, L and B. Several clues
indicate that the overexpression of Cat K is intimately
related to the fibrogenic process. First, the increased Cat K
mRNA content in the lung of silica-treated mice was max-
imal after 1 month, i.e. when extracellular matrices start to
accumulate, and remained elevated when fibrosis was
clearly established (after 2 months). In the resolutive
model of bleomycin-induced fibrosis, Cat K overexpres-
sion also slightly preceded collagen accumulation but
returned to its basal level when the lung collagen content
started to decrease (unpublished observation). These
results show that Cat K expression is apparently modu-
lated in parallel with collagen accumulation. Secondly,
while silica particles induced a strong upregulation of Cat
K in the lung, instillation of inert (WC) or inflammatory
(MnO2) particles had no or little effect on its expression.
These data, together with the fact that Cat K is also upreg-
ulated in patients suffering from different interstitial lung
diseases and in mice instilled with bleomycin [23,24],
support a particular role of Cat K in lung fibrotic diseases
with various origins.
Two months after silica instillation, homogenates of sili-
cotic lungs were shown to have a much higher Cat K
activity than control lungs. This indicates that, despite the
presence of endogenous cathepsin inhibitors in the cyto-
plasm of most cells [40], it is possible to measure changes
in Cat K activity in this kind of sample. It also shows that
pulmonary overexpression of Cat K transcripts correlates
with an increase of its activity in lung homogenates 2
months after instillation, which corresponds to the maxi-
mal collagen accumulation.
We further characterized the contribution of Cat K in the
development of lung fibrosis in the silica model by inves-
tigating its expression in "fibrosis-resistant" and "fibrosis-
prone" mouse strains. We found higher levels of Cat K
transcripts in the lungs of resistant (BALB/c) than sensitive
(C57BL/6) mice in response to silica particles. These
observations indicate that a high level of Cat K expression
is associated with a low fibrotic response in the present
model. Overall, our data, together with the fact that mice
deficient for Cat K developed significantly more fibrosis
than wild type counterparts after bleomycin instillation
[24], indicate that Cat K might play a protective role in sil-
ica-induced lung fibrosis. This also illustrates that, during
pulmonary fibrosis, not only profibrotic but also antifi-
brotic factors can be (over)produced and that fibrosis
results from the inappropriate balance between these.
In bleomycin-induced lung fibrosis, qualitative immu-
nostaining of lung sections have shown epithelial cells,
macrophages and fibroblasts as Cat K producing cells
while normal lungs expressed Cat K in epithelial cells and
macrophages [24]. The same authors also showed that
lung fibroblasts were the main contributors of Cat K over-
expression in fibrotic human lungs. In silica-induced lung
fibrosis, alveolar macrophages contribute to the installa-
tion of a chronic inflammation by producing several
mediators leading to the recruitment and activation of
other inflammatory cells [41-43]. Lung fibroblasts locate
more downstream of the process by mainly
overproducing components of the ECM, resulting in the
excessive accumulation of ECM in the lung parenchyma
[44]. Because of their central role in the induction of a
fibrotic response induced by silica, Cat K expression was
examined in these cell types. Both alveolar macrophages
and lung fibroblasts were found to contribute to the over-
expression of Cat K in silicotic lungs.
We confirm the overexpression of Cat K by fibrotic fibrob-
lasts and suggest the macrophage as another overproduc-
ing cell in murine silicotic lungs. We can, however, not
exclude that epithelial cells also contribute to the
increased expression of Cat K in the lungs of these mice.
To identify regulators of Cat K expression, we tested the
influence of several mediators involved in the pathogene-
sis of pulmonary fibrosis. We mainly concentrated our in
vitro study on fibroblasts because this cell type has been
found to overexpress Cat K in both human and mouse
fibrotic lungs [24]. It is already well established that sev-
eral factors, such as cytokines, can modify the expression
or the secretion of cathepsins in vitro or in vivo [45-48]. We
chose to test cytokines and factors known for their differ-
ent activities on the development of lung fibrosis: proin-
flammatory (IL-1β and TNF-α), profibrotic (IL-4 and TGF-
β) and antifibrotic mediators (IL-9 and PGE-2). None of
the molecules tested in vitro could reproduce the overex-
pression of Cat K observed in the lungs of silica-treatedRespiratory Research 2005, 6:84 http://respiratory-research.com/content/6/1/84
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Cat K expression is reduced in response to TGF-β1 in control and silicotic mouse lung fibroblasts Figure 5
Cat K expression is reduced in response to TGF-β1 in control and silicotic mouse lung fibroblasts. Cat K mRNA quantification 
in pulmonary fibroblasts of C57BL/6 mice. (A) Control fibroblasts were incubated with 1 or 10 ng cytokine/ml. Bars represent 
the mean of triplicate measurements of Cat K expression on the same sample. The Cat K downregulation by TGF-β was 
reproduced in 4 independent experiments. (B) Fibroblasts from control (pool of 10 animals) and silicotic (pool of 7 animals, sil-
ica) mice collected 2 months after instillation and incubated at least in duplicates without (non-treated) or with 10 ng TGF-β1/
ml (TGF-beta). The results are representative of 2 independent experiments (P < 0.001 in this experiment between non-
treated and TGF-β treated fibroblasts, either control or silicotic). Values are presented as means ± SEM.
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mice. Some proteases are known to be upregulated by
components of the organic extracellular matrix [49-51].
Fibronectin but not type I collagen has been found to
increase Cat K mRNA expression in osteoclasts cultures
[52]. Studies have shown that fibronectin starts to be
overproduced earlier than collagen in the fibrotic process
both in human fibrosis and mouse models of silica- and
bleomycin-induced lung fibrosis [33,53,54]. It is therefore
tempting to postulate that fibronectin or other compo-
nents of the ECM could contribute to the upregulation of
Cat K in vivo. The fact that two important proinflamma-
tory cytokines did not modify Cat K expression and that
inflammatory particles (MnO2) had only little effect on its
expression compared to fibrogenic particles (silica), sug-
gests that the inflammatory response induced by the
instillation of silica probably plays a limited role in the
induction of Cat K.
TGF-β is able to stimulate fibroblast proliferation and
expression of ECM proteins by these cells [37]. It has also
been shown to stimulate the production of the protease
inhibitor TIMP-1 [55] and to downregulate some pro-
teases, such as MMP-1, Cat B and L [45,55]. We show for
the first time that the expression of a highly collagenolytic
protease, Cat K, is repressed by this growth factor in colla-
gen overproducing cells, i.e. fibrotic fibroblasts. The fact
that TGF-β reduced Cat K expression in both control and
silicotic mouse fibroblasts, as well as in human pulmo-
nary fibroblasts suggests similar modes of regulation.
Interestingly, although it has been shown that TGF-β
represses Cat K expression in monocyte-derived osteo-
clasts [56], we did not find a similar effect on alveolar
macrophages, although these cells seem to express both
TGF-β receptors [57]. This might imply different TGF-β
signaling pathways in both cell types.
TGF-β has been detected in several forms of lung fibrosis.
In idiopathic pulmonary fibrosis, TGF-β located to
activated foci [58]. Similarly, in silicosis, this growth fac-
tor was found to co-localize with silicotic granulomas
both in rodents and humans [59,60]. We could therefore
speculate that the presence of TGF-β at sites of high colla-
gen production could repress the expression of Cat K by
fibroblasts, limiting its potential antifibrotic activity. One
argument in favor of this hypothesis is the stronger accu-
mulation of Cat K transcripts in "fibrosis-resistant" BALB/
c mice than in "fibrosis-prone" C57BL/6 mice in silica-
instilled animals. Although the exact reasons for this dif-
ference in the fibrotic response between these two strains
are still unclear, some evidence point to TGF-β as a key
player in this phenomenon. First, because of its well-char-
acterized profibrotic activity already mentioned. Sec-
ondly, we showed that TGF-β content increased in
response to silica in the lungs of C57BL/6 but not BALB/c
mice, confirming that TGF-β is more expressed in fibrosis-
sensitive mouse strains than in fibrosis-resistant strains in
response to fibrogenic stimuli [33-35]. Overall, these
observations suggest that Cat K might be one of the down-
stream targets of TGF-β that could account for the differ-
ence of strain sensitivity, as it was recently proposed for
TIMP-1 and the connective tissue growth factor [61,62].
Conclusion
We have shown that the most potent collagenolytic mam-
malian protease, Cat K, is upregulated during a fibrotic
process induced by the instillation of crystalline silica par-
ticles in mice. The expression level of Cat K was inversely
associated with the susceptibility of murine strains to
develop fibrosis in response to silica, suggesting that Cat
K might contribute to limit lung fibrosis. Our in vitro and
in vivo data support the view that the profibrotic growth
factor TGF-β represses the expression of Cat K in lung
fibroblasts to allow the development of fibrosis.
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